# Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations

> **NCT05904730** · PHASE1 · COMPLETED · sponsor: **Lynkcell Europe** · enrollment: 10 (actual)

## Conditions studied

- Breast Cancer
- Ovarian Cancer
- Breast Neoplasms
- Ovarian Neoplasms
- BRCA Mutation
- HER2-positive Breast Cancer
- HER2-negative Breast Cancer
- HER-2 Protein Overexpression

## Interventions

- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT05904730
- **Lead sponsor:** Lynkcell Europe
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-11
- **Primary completion:** 2024-11-09
- **Final completion:** 2024-12-26
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05904730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05904730, "Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05904730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*